ACADIA Pharmaceuticals Inc. (0A4W.L)

16,33 -0,33 (-1,98%) In data: 06:43PM BST. Mercato aperto.

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 597

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Stephen R. Davis J.D.	President, CEO & Director	1,46M	N/D	1961
Mr. Mark C. Schneyer	Executive VP & CFO	701,03k	N/D	1975
Mr. Brendan P. Teehan	Executive VP, COO & Head of Commercial	724,31k	N/D	1969
Mr. James K. Kihara	VP, Chief Accounting Officer & Corporate Controller	N/D	N/D	1981
Dr. Elizabeth H.Z. Thompson Ph.D.	Executive VP & Head of Research and Development	N/D	N/D	1976
Mr. Benir Ruano	Senior Vice President of Technical Development & Operations	N/D	N/D	N/D
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Jennifer J. Rhodes J.D.	Executive VP, Chief Legal Officer & Secretary	N/D	N/D	1970
Ms. Julie Fisher	Senior Vice President of Marketing & Commercial Strategy	N/D	N/D	N/D
Ms. Holly Valdiviez	Senior VP & Head of Sales	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di ACADIA Pharmaceuticals Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.